Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.